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developed in NSCLC, has been established here in SCLC. Patients on amrubicin
experienced less symptom deterioration during treatment.
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OBJECTIVES: Gain insights into Health Technology Assessment (HTA) agencies
expectations regarding Health-Related Quality of Life (HRQoL) for cost-effective-
ness evaluations of new medications for treating Castration-Resistant Prostate
Cancer (CRPC). METHODS: In January 2012, 61 HTA agencies websites were
scanned to identify HTAs of newmedications for the treatment of CRPC published
from 2005 to present. Only those evaluating the cost-effectiveness of new technol-
ogies were retained and analyzed for a better understanding of HTA agencies’
expectations regarding HRQoL in CRPC. RESULTS: 39 HTAs were identified, 12 of
which are currently in progress. The 27 published reports comprised 12 technology
appraisals, 9 horizon scanning reports and 6 literature reviews. Only 9 of the 12
technology appraisals evaluated cost-effectiveness, these included seven apprais-
als on three drugs: IQWiG (Germany) assessed abiraterone; NICE (England &Wales)
accepted docetaxel and rejected cabazitaxel; SMC (Scotland) rejected docetaxel
and cabazitaxel; CVZ (Netherlands) accepted cabazitaxel; PBAC (Australia) ac-
cepted docetaxel after two rejections and rejected cabazitaxel. Uncertainty regard-
ing HRQoL measures was the most often cited negative comment. For both do-
cetaxel and cabazitaxel, the absence of quality of life measures from the main
phase III trials and uncertainty around utility values were cited as reasons for
rejection by NICE, SMC and PBAC. The CVZ accepted cabazitaxel for temporary
reimbursement on the understanding that further subpopulation analysis and
more data on utilities will be needed. The IQWiG assessment of abiraterone com-
mented on uncertainties regarding the validity of the QoL questionnaire and re-
strictions in subgroup analyses. CONCLUSIONS: Our review indicates the need to
include comprehensive quality of life measures in phase III trials for new drugs to
treat CRPC, ensure these can be mapped into robust utility values and conduct
meaningful CRPC subpopulation analyses. Further insights will be gained in the
near future with the publication of CRPC HTAs currently in progress.
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PATIENT REPORTED OUTCOMES IN ONCOLOGY CLINICAL TRIALS: ARE YOU
CAPTURING THE LINGUISTIC DIVERSITY OF THE PATIENT POPULATION IN
INDIA?
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OBJECTIVES:Data collected using patient reported outcomes (PRO) tools in clinical
trials provide unique information about patients’ experience with their treatment.
One of the major challenges with conducting clinical trials in linguistically diverse
countries such as India, however, is identifying and using PRO scales that are
linguistically validated in most of the representative regional languages. Lack of
availability of linguistically validated scales can limit the participation of a relevant
population from clinical trials. Therefore, the objective of this study was to deter-
mine if the PRO instruments used in clinical trials are linguistically validated in
local languages across the various regions in India. For this study we limited our
therapeutic area focus to clinical trials conducted in oncology. METHODS: A de-
tailed review of the registered trials in clinicaltrials.gov was conducted using qual-
ity of life (QoL) and oncology as keywords. Identified articles (n103)were screened
to exclude trials where QoL was not measured and studies with n 	 30. ProQoLID
and official websites of questionnaires were used to determine the availability of
translations and linguistic validity of the questionnaires included in clinical trials.
RESULTS: EQ-5D is the most commonly used generic instrument in oncology trials
and is validated in most 11 Indian languages. EORTC-QLQC30, EORTC-QLQH&N35,
EORTC-QLQBR23 and EORTC-QLQLC13 are the most commonly used cancer spe-
cific instruments and are validated in approximately 10 Indian languages. None of
the generic or disease specific cancer instruments have been translated or linguis-
tically validated for the Eastern & North-Eastern regions in India in languages such
as Oriya, Santhali, Assamese, and Manipuri thereby limiting the participation of
patients from these regions in clinical trials. CONCLUSIONS: The results of our
analysis indicate that future efforts need to focus on translating and validating PRO
instruments in 14 different Indian languages that should include the North Eastern
regions of India.
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OBJECTIVES: Antidepressants (ADs) are primarily used to treat depression and anxi-
ety among individuals with cancer and depression; however ADs are also being used
for symptomatic relief from hot-flashes, neuropathic-pain, and fatigue in this popu-
lation. Although there is a lack of robust evidence on the effectiveness of ADs in this
population, and conflicting reports of a possible association between AD use and risk
of recurrenceof certaincancersexists;ADsarestill beingprescribed in thispopulation.
Thus, the objective of this studywas to systematically review the extent of anyADuse
among individuals with cancer. METHODS: A systemic literature search was con-
ducted using 4 electronic databases (PubMed, CINHAL, PsychINFO, and Web-of-Sci-
ence), and cross-referencing. Studies starting from1975 to 2011, and fromall countries
were assessed. Eligibility criteria used for the extraction of studies included: 1)full
articles published in peer-reviewed journals in English-language only; 2)observational
studieswithdata onanyuse or prescription ofADs; and 3)adults and children aged1
year diagnosed with cancer (all types and stages of cancer were included). Studies on
the use of psychotropic agents other thanADs or psychotherapywere excluded. After
data extraction, number and percentages of individuals with cancer using ADs were
calculated.RESULTS:The search yielded 1880 studies, 14 ofwhichmet thepredefined
inclusion criteria. Overall, the rates of AD use ranged from 1%-26% in varying sub-
groupsof cancerpatients;with lower rates inpediatric cancerpatients (7%-12.3%), and
in those with advanced-stage cancers (7.4%-16%). Rates also varied according to the
type of cancers: breast (11.5%-34%), prostate (7%-18.8%), colon (7.5%-17.3%) and lung
(7.2%-13.7%). The rates were higher among individuals with cancer and clinically di-
agnosed depression (12%-66.6%). CONCLUSIONS: Our descriptive results suggest
that ADusemay be associatedwith cancer site and stage, and presence of clinically
diagnosed depression; and is lower in pediatric and advanced-stage cancer pa-
tients.
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OBJECTIVES: Hypomethylating agents (HMAs), decitabine and azacitidine, are in-
dicated for use in treatment of myelodysplastic syndromes (MDS), however only a
minority of patients receive HMAs. Our objective was to examine patterns of treat-
ment associated with FDA-approved 5-day decitabine (DEC-5) and 7-day azaciti-
dine (AZA-7) and off-label 5-day azacitidine (AZA-5) in MDS patients. METHODS:
We identified MDS patients with an initial HMA treatment between July 1, 2005 to
June 30, 2009 in 2 large insurance claims databases. Index date was the date of
initial HMA treatment. Patients were stratified into: DEC-5, AZA-7, or AZA-5, based
on their first cycle of treatment and were followed for 6 months. We described the
number of unique cycles of index treatment and treatment gaps (days of missed
treatment) in these groups. RESULTS:We identified 18,706 patients with MDS; 546
were treated with HMAs and were included in the study (156 received DEC-5, 176
received AZA-5 and 214 received AZA-7). Mean age was similar across groups:
68.8-71.2 years. Neutropenia was more common before treatment initiation in the
DEC-5 (34.6%) group than in AZA-5 (22.7%) and AZA-7 (26.6%; p.05) groups. There
were 1,701 treatment cycles: 431 DEC-5 (per patient mean:2.8; median:2), 586 for
AZA-5 (mean:3.3; median:3), and 684 for AZA-7 (mean:3.2; median:3) (p0.05 for
means). DEC-5 cycles had the fewest gaps: 94.9% had no treatment gaps, compared
to 89.1% for AZA-5 and 23.4% for AZA-7. Among DEC-5 cycles, 3.2% had a 2 day gap,
compared to 7.2% for AZA-5 and 66.5% for AZA-7 (p0.001). CONCLUSIONS: In this
retrospective claims analysis, few MDS patients were treated with HMAs. Among
those who received HMAs, decitabine patients were more likely to have prior neu-
tropenia. Between the 2 FDA-approved regimens, DEC-5 and AZA-7, there were
significantly fewer gaps with decitabine treatment. More treatment gaps were ob-
served with use of longer AZA regimen.
PCN116
USING THE MODIFIED RAND/UCLA DELPHI PROCESS TO PRODUCE TREATMENT
CONSENSUS IN UNRESECTABLE MIDGUT GASTROINTESTINAL
NEUROENDOCRINE TUMORS
Strosberg JR1, Fisher G2, Benson AB3, Malin JL4, Anthony L5, Arslan B1, Gibbs JF6,
Greeno E7, Iyer R6, Kim MK8, Maples W9, Philip PA10, Wolin E11, Cherepanov D12,
Broder M12
1University of South Florida College of Medicine, H. Lee Moffitt Cancer Center and Research
Institute, Tampa, FL, USA, 2Stanford University Medical Center, Stanford, CA, USA, 3Robert H.
Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA, 4University of
California-Los Angeles, Los Angeles, CA, USA, 5University of Kentucky Medical Center,
Lexington, KY, USA, 6State University of New York at Buffalo, Roswell Park Cancer Institute,
Buffalo, NY, USA, 7University of Minnesota, Minneapolis, MN, USA, 8Mount Sinai Medical
Center, New York, NY, USA, 9Mission Health System, Asheville, NC, USA, 10Wayne State
University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA, 11Samuel Oschin
Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 12Partnership for Health
Analytic Research, LLC, Beverly Hills, CA, USA
OBJECTIVES: Comprised of carcinoid and pancreatic neuroendocrine tumors
(NETs), gastrointestinal NETs give rise to diverse clinical syndromes. Current treat-
ment guidelines lack some specificity. We summarize an expert panel consensus
on medical treatment of well-differentiated (grade 1-2) unresectable midgut NETs.
METHODS:ThemodifiedRAND/UCLADelphi processwas used to collectNET treat-
ment appropriateness ratings. The process involved recruitment of physician ex-
perts (e.g., by specialty, geography, practice), literature review, and collection of
ratings before and after a face-to-face discussion. Experts and moderator were
blinded to funding source. Patient scenarios were rated on a 1-9 scale on appropri-
ateness of various therapies and were labeled as appropriate, inappropriate, or
uncertain. Scenarios with2 ratings in 1-3 and2 in 7-9 range were considered to
have disagreement. RESULTS: Panelists (age: 38-63 years) were from northeast,
midwest, south, and west regions. Panelists had practiced for a mean 15.5 years
and reported seeing 25 to 800NETpatients per year. Panelists rated 202 scenarios in
midgut NETs. The proportion on which there was disagreement decreased from
11.7% (23 scenarios) before the meeting to 4.5% (9) after. After the meeting, 49% (99
scenarios) were rated inappropriate, 29.7% (60) were uncertain, and 16.8% (34) were
appropriate. Resulting consensus statements include: 1) it is appropriate to use
somatostatin analogs as 1st-line therapy in all patients; 2) it is appropriate to in-
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crease the dose/frequency of octreotide-LAR as 2nd-line therapy in patients with
uncontrolled symptomsup to 60mg every 4weeks or up to 40mg every 3 or 4weeks
for refractory carcinoid syndrome; and 3) as 3rd-line therapy, antiangiogenic ther-
apy may be active in patients with carcinoid tumors. CONCLUSIONS: Treatment
consensus obtained in this study is concordant with NCCN recommendations. The
Delphi process, however, permittedmore detailedmedical treatment guidelines in
a range of key areas in midgut NETs.
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OBJECTIVES: Gastrointestinal neuroendocrine tumors (NETs) are rare and current
treatment guidelines lack specificity in some clinical areas. We present a panel
consensus on medical treatment of well-differentiated (grade 1-2 tumors) unre-
sectable non-pancreatic non-midgut NETs. METHODS: NET treatment appropri-
ateness ratings were collected using the RAND/UCLA Delphi process. We recruited
physician experts (criteria: specialty, geography, practice), reviewed NET treat-
ment literature, and collected 2 rounds of ratings (before and after a face-to-face
meeting) from the experts. Experts and the moderator were blinded to the funding
source. Patient scenarios (rated on a 1-9 scale indicating appropriateness of various
interventions for a given scenario) were labeled as appropriate, inappropriate, or
uncertain. Scenarios with 2 ratings from 1-3 and 2 from 7-9 range were consid-
ered to have disagreement and were not assigned an appropriateness rating.
RESULTS: Ten panelists had amean age of 50.4 years. Specialties representedwere
medical and surgical oncology, interventional radiology, and gastroenterology, and
all practices were affiliated with academic institutions. Panelists had practiced
between 6-33 years. Among 202 non-midgut rated scenarios, disagreement de-
creased from 16.2% (32 scenarios) before the meeting to 3% (6) after. In the 2nd
round, 42.1% (85 scenarios) were rated inappropriate, 34.2% (69) were uncertain,
and 20.8% (42) were appropriate. Consensus statements from the scenarios in-
clude: 1) observation is appropriate in patients with no symptoms and low-volume
radiographically-stable disease; 2) somatostatin analogs may be appropriate in
patients with secretory symptoms; and 3) everolimus or interferon- can be con-
sidered in patients who progressed radiographically or symptomatically on soma-
tostatin analogs. CONCLUSIONS: We obtained appropriateness ratings of variety
medical therapies in NETs from expert physicians. The Delphi process enabled
participants to systematically quantify their assessment of the literature in a valid
and reliable way while improving overall panel consensus on the appropriateness
of medical therapies in non-midgut NETs.
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PROMOTING TOBACCO CESSATION AMONG CANCER PATIENTS: A NATIONAL
SURVEY AMONG ONCOLOGY PROVIDERS IN THE UNTIED STATES
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OBJECTIVES: Tobacco use following cancer diagnosis is a serious concern for neg-
ative health outcomes. Despite ill-effects of tobacco among cancer patients and
negative implications for treatment, many patients continue to use tobacco. On-
cologists have a pivotal role in promoting tobacco cessation throughout treatment.
This study assessed knowledge, readiness, and willingness to conduct and pro-
mote tobacco cessation counseling among a national sample of currently licensed
practicing US Oncology providers. METHODS: A brief survey was administered in
July 2011 via e-mail (N3006) and US postal mail (N1000). Samples were obtained
fromSK&A Information Services, Inc., which used verified addresses and broadcast
e-mail surveyswith one follow-up. Response rateswere 0.6% for e-mail (N19) and
9.6% for postal mail (N96), with a 2.9% overall response rate (N115). RESULTS:
Results showed a majority of oncologists do the following often/almost always
with patients: ask about tobacco use (96.6%); document tobacco use (93.1%); discuss
tobacco use as a cancer risk factor (87.9%); counsel patients on quitting (72.8%); and
assess readiness to quit (68.7%). Findings, however, also reported a majority of
oncologists do the following never/rarely with patients: provide information about
secondhand tobacco smoke (53.5%); provide information on quitlines (59.7%); pro-
vide brochures and self-help guides (64.3%); and follow the 5A’s model for tobacco
treatment (68.6%). On a scale of 0-10, providers indicated they were generally com-
fortable providing cessation counseling [mean7.0; SD2.4]; however, providers
were lesswilling to participate in a tobacco cessation training program for assisting
patients with quitting [mean5.2; SD3.4]. CONCLUSIONS: Findings suggest on-
cology providers are asking, documenting use, and counseling patients who con-
tinue to use tobacco during treatment. Education targeting providers can increase
knowledge and practices related to the 5A’s treatment model, promoting quitline
and self-help information for patients. Effective strategies increasing providerwill-
ingness to attend tobacco treatment training sessions should also be encouraged.
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OBJECTIVES: The main objective was to determine the chemotherapy treatment
and outcome.METHODS:Datawas collected from1 June 2008 till 31 December 2008
in Hospital Kuala Lumpur (HKL) using web-based application. Survival data would
be obtained via linkage with Registration Department after four years. Data anal-
ysis was with STATA statistical software. RESULTS: The total number of patients
was 1192.There were 56% females and the most common age group was 50-59
years. The major ethnic groups were Malay (46.5%), Chinese ( 37.3%) and Indians (
13.8%). Most patients at the oncology clinic at HKL have good performance status
with ECOG 0-1 (61.5%). The most prevalent cancers were breast cancer (24.5%),
colorectal cancer( 17.4%), bronchus and lung cancer 8.6%, cervical cancer 6.5% and
nasopharyngeal cancer (NPC) 6.2%. Most solid tumours were treated by multimo-
dality. 48.8% received 2 or more modalities . There were 547 patients (45.9%) that
received radiotherapy and 32.2% that received chemotherapy. 384 patients were
given cytotoxic chemotherapy .Most patients (84,1%) received just one regime. The
most common regime was a combination of Fluorouracil, Epirubicin and Cyclo-
phosphamide ie FEC (16.4%.) The most often used cytotoxic drugs used were Fluo-
rouracil (26.3%), Cisplatin (15%) followed by Cyclophosphamide (9.9%), Epirubcin
(7.3%), Capecitabine ( 6.4%), Docetaxel (4.2%), Gemcitabine (3.7%). The most often
used route of administration was intravenous ( 92.6%) mostly infusion as opposed
to bolus. Capecitabine was the cytotoxic dug that was the most widely used in the
oral form.CONCLUSIONS:This is only sub-study of a long term research that began
in 2008 in HKL.. Patterns in chemotherapy usage would change as new drugs
emerged in the Formulary. The database would be sustained as a platform for
future researches and for survival analysis. (283 words).
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OBJECTIVES: In 2001, Thailand implemented the 30 Baht Scheme, a public insur-
ance scheme that covers the poor and uninsured and pays providers through a
capitated payment scheme. Our objective is to evaluate the impact of the 30 Baht
Scheme on use of medicines in Thailand for three non-communicable diseases:
cancer, cardiovascular disease, and diabetes. METHODS: We used an interrupted
time series design to measure the impact of the 30 Baht Scheme on total pharma-
ceutical market volume and market share. We used IMS Health data on quarterly
purchases of medicines from hospital and retail pharmacies from 1998 to 2006.
RESULTS: The 30 Baht Schemewas associatedwith long-term increases in hospital
sector sales of medicines for conditions that can be adequately treated in outpa-
tient and primary care settings (e.g., diabetes, high cholesterol and high blood
pressure). The policy was associatedwith no change in sales ofmedicines formore
life-threatening diseases, which are more appropriately treated in secondary or
tertiary settings (e.g., myocardial infarction, stroke and cancer). The majority of
sales were for essential medicines, yet there were also post-policy increases for
non-essential medicines. Immediately following the reform, there was a signifi-
cant shift in hospital sector market share by licensing status for most classes of
medicines. We observed large increases in government-produced products, pri-
marily at the expense of branded generics.CONCLUSIONS:Our results suggest that
expanding health insurance coverage with a medicines benefit to the entire Thai
population increased the volume of medicine sales in primary care hospitals. Our
study, however, also suggests that implementation of the 30 Baht Scheme may
have been associated with possibly undesirable effects: increased use of non-es-
sential medicines and decreased use of less expensive generics and medicines in
secondary and tertiary settings. Thorough evaluation of desired and undesired
effects of universal health insurance programs are urgently needed.
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OBJECTIVES: To compare the demographic, clinical and treatment characteristics
of post-menopausal women with advanced ER/HER2- breast cancer (BC) treated
with aromatase inhibitors (AI) who experienced 0 or 1 AI failure (AIF).METHODS:
Women  55 years old, newly diagnosed with metastatic ER/HER2- BC (index)
were identified from the 2006-2010 Thomson Reuters MarketScan databases. Patients
in the 6-month pre- or variable post-index periods treated with endocrine (ET:
tamoxifen, fulvestrant) or AI (anastrozole, letrozole, or exemestane) therapy (ER)
and not with trastuzumab or lapatinib (HER2-), with no pre-index diagnosis of
primary cancer other than BC, and post-index treatmentwith 1 AI were retained.
AIFwas defined post-index as a switch to an alternative AI, ET, or chemotherapy, or
AI discontinuation with no further BC treatment. RESULTS: Among 4274 ER/
HER2- BC patients studied, 61% had 1 AIF (80% had 1 and 20% had 2AIFs). There
was no difference in pre-index AI use (54.4% no AIF, 51.8% AIF; p0.093). At index,
AIF patientsweremore likely to beMedicare-eligible (57% vs. 51%)with liver (7% vs.
4%), lung (10% vs. 8%), bone (56% vs. 48%), and brain (7% vs. 5%) metastases, all
p0.03. Mean follow-up days was shorter for AIF patients (486 vs. 522, p0.006).
First line AI and ET treatments were respectively 95% and 5% for AIF and 97% and
3% for no AIF patients. The most common first line therapy was anastrazole (49%
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